New $90 million annual addressable market for QHSLab's latest product, the Allergy Quick Test, branded AllergiQT(TM).

Stock Information for QHSLab Inc - Class A

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About QHSLab Inc - Class A

QHSLab Announces Impressive 2023 Fiscal Year Results with Growing Revenues, Improved Gross Margins, and Substantial Reduction in Net Loss
QHSLab Integrates Digital Medicine Assessments into Prominent Electronic Health Record (EHR) Company
QHSLab, Inc. (USAQ) Reports Third Quarter Financial Results
QHSLab Welcomes Six New Integrated Service Program (ISP) Customer Accounts and Launches Enhanced Website for Improved Customer Engagement
QHSLab Continues to Lead the Way in Digital Healthcare with Impressive Year-to-Date Achievements in Patient-Centric Innovations and Advancements in Behavioral Healthcare 
QHSLab, Inc. Reports First Quarter Financial Results
QHSLab, Inc. Announces Representation Agreement with Healthcare Information Technology Specialists of Florida
QHSLab, Inc. Reiterates its 2022 Projection of a $7.5 Billion Addressable Market for its Integrated Service Program (ISP) Digital Health Solution Designed For Primary Care

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.